Summary:
- The article discusses the development of a new vaccine candidate against COVID-19 by Bharat Biotech, an Indian biotechnology company.
- The vaccine, named COVAXIN, is currently in phase 3 clinical trials and has shown promising results in the earlier phases, demonstrating a high level of safety and immunogenicity.
- The article highlights the potential of COVAXIN to contribute to the global effort in combating the COVID-19 pandemic, as it could provide an additional vaccine option for countries around the world.